Evaluating the L-MIND and RE-MIND2 Trials in the Real-World Setting

In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.